Colca J R, Wyse B M, Sawada G, Jodelis K S, Connell C L, Fletcher-McGruder B L, Palazuk B J, Diani A R
Diabetes & GI Diseases Research, Upjohn Company, Kalamazoo, MI 49001.
Metabolism. 1988 Mar;37(3):276-80. doi: 10.1016/0026-0495(88)90108-4.
Chronic administration of ciglitazone (5-4[1-methyl-cyclohexylmethoxy)-benzyl]-thiazolidine-2,4 dione) decreased both plasma glucose and insulin concentrations in ob/ob mice. When given as an admixture to the feed, blood glucose levels were reduced as early as 12 hours after initiation of treatment. Concomitant with the decrease in circulating insulin, there was an increased hormone content in the beta-cells as judged by RIA and aldehyde-fuchsin staining. Acute oral dosing with ciglitazone produced a 41% reduction in circulating insulin at a time when glucose concentrations were as yet unaffected. Ciglitazone also inhibited glucose-stimulated insulin secretion in vitro. The results suggest that the hypoglycemic agent, ciglitazone, may reduce plasma glucose and insulin concentrations at least partially as the result of independent mechanisms.
